On this page
Quick Reference
Overview and Recommendations
Background
Evaluation
Management
Board Review — High Yield
- •HFE C282Y homozygosity, accounts for ~90% of hereditary hemochromatosis cases in Northern European populations; penetrance is ~28-50% in men but only 1-5% in premenopausal women.
- •Ferritin >1000 μg/L, single strongest predictor of cirrhosis (OR 15.6); 45% of such patients have bridging fibrosis or cirrhosis on biopsy.
- •Fasting TSAT >45% (women) or >50% (men), earliest and most sensitive biochemical marker of iron loading; prompts HFE genotyping.
- •Ferroptosis, iron-dependent, non-apoptotic cell death pathway (lipid peroxidation) driving hepatocellular injury in hemochromatosis; distinct from apoptosis.
- •Type 4A ferroportin disease (SLC40A1 loss-of-function), autosomal dominant; high ferritin with normal TSAT; phlebotomy causes iatrogenic anemia and is poorly tolerated.
- •Juvenile hemochromatosis (HJV or HAMP mutations), presents before age 30 with severe cardiomyopathy and hypogonadism; rapid progression to death by age 40 if untreated.
- •Therapeutic phlebotomy, 500 mL every 1-2 weeks until ferritin <50 μg/L; maintenance every 2-4 months to keep ferritin <100 μg/L and TSAT <50%. NNT to prevent one death = 6 if started before ferritin >1000 μg/L.
- •Pantoprazole 40 mg/day, reduces phlebotomy need by 33% by impairing intestinal iron absorption (Fe³+ to Fe²+ reduction).
- •HCC surveillance, abdominal ultrasound every 6 months for all patients with cirrhosis (F4) or advanced fibrosis (F3); continue indefinitely even if fibrosis regresses.
- •Liver transplantation, cures hepcidin deficiency (donor liver expresses normal HFE); 5-year survival ~77.5% (UNOS 2003-2019); outcomes comparable to other CLD etiologies.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Hepcidin deficiency is central defect; leads to unregulated iron absorption.
- ▸Four types: Type 1 (HFE) most common; Type 4A (ferroportin disease) responds poorly to phlebotomy.
Hemochromatosis is a genetically heterogeneous disorder of iron metabolism characterized by excessive intestinal iron absorption leading to toxic deposition in the liver, heart, pancreas, joints, and skin [4]D5. It results from insufficient hepcidin activity, causing unregulated iron entry into the circulation [4]D5. Without early intervention, cumulative iron overload causes cirrhosis, diabetes mellitus, cardiomyopathy, arthropathy, and hepatocellular carcinoma [4]D5[6]D5. The 2022 BIOIRON Society consensus classifies subtypes: Type 1 (HFE) , most common, autosomal recessive, p.Cys282Tyr mutation; Type 2A/2B (Juvenile) , severe early onset; Type 3 (TFR2) ; Type 4A (Ferroportin disease) , loss-of-function, responds poorly to phlebotomy; Type 4B (Ferroportin disease with hepcidin resistance) , gain-of-function, responds to phlebotomy [4]D5. Key terms: Transferrin saturation (TSAT) >45% is earliest marker; Serum ferritin >300 ng/mL (men) or >200 ng/mL (women) warrants investigation; Hepatic iron concentration (HIC) >80 µmol/g dry wt increases cirrhosis risk [4]D5. Pearl: Hemochromatosis is not a single disease but a family of genetic disorders united by hepcidin insufficiency; the 2022 BIOIRON molecular classification dictates both prognosis and treatment strategy, and recognizing that type 4A (ferroportin disease) requires different management than other subtypes avoids iatrogenic harm [4]D5.
| Subtype | Gene (Protein) | Inheritance | Key Features |
|---|---|---|---|
| Type 1 (HFE-related) | HFE (HFE) | Autosomal recessive | Most common (≈90% of cases in populations of Northern European descent). Onset typically after age 40. Variable penetrance; the p.Cys282Tyr (C282Y) mutation accounts for the majority. |
| Type 2A (Juvenile) | HJV (hemojuvelin) | Autosomal recessive | Severe, early-onset (first to third decade). Rapid iron loading leading to heart failure and hypogonadism before cirrhosis. Hepcidin levels profoundly low. |
| Type 2B (Juvenile) | HAMP (hepcidin) | Autosomal recessive | Clinically indistinguishable from type 2A. True hepcidin deficiency. Extremely rare. |
| Type 3 (TFR2-related) | TFR2 (transferrin receptor 2) | Autosomal recessive | Intermediate phenotype between types 1 and 2. Onset in adulthood but often more aggressive than HFE-HC. |
| Type 4A (Ferroportin disease) | SLC40A1 (ferroportin) | Autosomal dominant | Loss-of-function mutation → impaired iron export from macrophages → predominant reticuloendothelial iron loading. Milder course, often with anemia of chronic disease and early hyperferritinemia but low transferrin saturation. |
| Type 4B (Ferroportin disease with hepcidin resistance) | SLC40A1 (ferroportin) | Autosomal dominant | Gain-of-function mutation → ferroportin resistant to hepcidin-induced degradation → same effect as hepcidin deficiency. Phenotype resembles type 1 but may be more severe. |
Pathophysiology & Mechanism
- ▸Hepcidin deficiency → unregulated ferroportin → iron overload.
- ▸Ferroptosis and ductular reaction drive fibrosis; cirrhosis risk modified by sex, alcohol, diabetes.
The central defect is loss of hepcidin, the iron-regulatory hormone, causing unregulated ferroportin activity and excessive dietary iron absorption [20]D5[21]D5. In HFE hemochromatosis, C282Y mutation impairs BMP6-SMAD signaling, reducing hepcidin transcription [20]D5[23]C4[32]D5. Iron in its labile form (NTBI) catalyzes Fenton chemistry, generating ROS and triggering ferroptosis, an iron-dependent cell death pathway [10]C4[15]D5[18]C4. Hepatocytes are primary targets. Iron-loaded hepatocytes undergo senescence, activating the ductular reaction (DR) , a fibrogenic progenitor cell response [13]B3b[14]C4. DR correlates more strongly with fibrosis stage than hepatic iron concentration alone [13]B3b. Sustained stellate cell activation leads to cirrhosis and [29]C4. Progression risk is increased by male sex, alcohol (>60 g/day), and diabetes [9]B3b. Hepatocellular carcinoma (HCC) risk is elevated due to oxidative DNA damage and genomic instability [16]D5[20]D5. Extrahepatic iron deposition causes cardiomyopathy, hepatogenous diabetes, arthropathy, and skin hyperpigmentation [20]D5[24]A1a[32]D5. Pearl: The fundamental defect in hereditary hemochromatosis is hepcidin deficiency, which causes unregulated iron absorption and progressive parenchymal iron loading; ferroptosis is the dominant cell-death pathway driving hepatocellular injury and fibrogenesis, and the ductular reaction is an early, iron-sensitive trigger of fibrosis that may precede stellate-cell activation [10]C4[13]B3b[20]D5[21]D5.
Epidemiology, Etiology & Risk Factors
- ▸C282Y homozygosity prevalence 1:200-300 in Northern Europeans; male sex and ferritin >1000 µg/L key risk factors.
- ▸HCC risk 1-3%/year in cirrhotics; increased infection risk with siderophilic bacteria.
C282Y homozygosity occurs in 1 in 200-300 Northern Europeans, highest in Ireland (carrier rate ~20%) [33]A1c[50]D5. In the US, ~1 million carry the genotype; most never develop overload [44]B2b. Penetrance: 28-50% of men but 1-5% of premenopausal women [33]A1c[50]D5. Risk factors for progression: serum ferritin >1000 µg/L (strongest predictor; 45% have advanced fibrosis), male sex, central adiposity (HR ~1.4-1.5) [42]B2b, heavy alcohol (>60 g/day; OR 3-5) [38]B2b[54]B2b, hepatitis co-infection [38]B2b, metabolic syndrome/NAFLD [35]A1a[16]D5, and TMPRSS6 A736V polymorphism [45]B3b. Genetic modifiers include variants near BMP2, BNP3L, HFE2 [61]B2b. Increased infection risk with siderophilic bacteria (Vibrio vulnificus, Yersinia enterocolitica) [25]D5[59]D5. Morbidity: cirrhosis (25-40% men), HCC (1-3% per year in cirrhotics), arthropathy (>50%), diabetes (20-30% cirrhotics), hypogonadism (10-20%), cardiomyopathy [33]A1c[47]B2b[50]D5[58]D5[60]D5. Pearl: In C282Y homozygotes, serum ferritin >1000 µg/L, male sex, central adiposity, and heavy alcohol consumption are the dominant, independently validated modifiers of progression to cirrhosis; these factors should be actively assessed in every patient at diagnosis to stratify risk and guide intensity of phlebotomy and surveillance [33]A1c[42]B2b[44]B2b[50]D5.
| Factor | Effect on Progression | Strength of Evidence |
|---|---|---|
| Male sex | 5-10 fold increase in clinical penetrance vs. premenopausal women | Consistent across major cohorts [33]A1c[44]B2b[50]D5 |
| Central adiposity (high waist-to-hip ratio) | HR for liver fibrosis/cirrhosis in C282Y homozygotes: increase per WHR unit (males: HR ~1.4; females: HR ~1.5) [42]B2b | Prospective cohort (UK Biobank), well-controlled |
| Heavy alcohol consumption (>60 g/day) | Synergistic liver injury; accelerates fibrosis progression; odds ratio for cirrhosis ~3-5 vs. non-drinkers [38]B2b[54]B2b | Several cohort studies; EASL guideline recognizes as key modifier [33]A1c |
| Hepatitis C or B co-infection | Increased risk of cirrhosis and HCC, independent of HFE genotype [38]B2b | Large retrospective Italian cohort |
| Metabolic syndrome / NAFLD | Additive hepatic inflammation and fibrosis risk; increases hepatic iron deposition [35]A1a[16]D5 | Meta-analysis (OR for NAFLD with C282Y ~1.3-1.5) [35]A1a; synergy with HFpEF-like cardiomyopathy [58]D5 |
| TMPRSS6 A736V polymorphism (rs855791) | The V allele (higher hepcidin) attenuates iron loading; TT genotype increases transferrin saturation by ~10% vs. AA [45]B3b | Case-control study with functional data |
| Compound heterozygosity (C282Y/H63D) | Low risk: biochemical iron elevation in ~25% but cirrhosis in <2% [41]B2b[54]B2b | Prospective population-based cohort [41]B2b |
| First-degree relative with known HH | Relative risk of carrying C282Y homozygosity is ~25% (siblings of proband) [48]B2b | Familial cascade testing data |
| Dietary iron intake | High heme iron intake modestly accelerates iron accumulation in C282Y homozygotes; effect small relative to genetic factors [44]B2b | Observational, not definitive |
| Vitamin D deficiency | Associated with increased liver fibrosis in chronic liver disease; may apply to HH [55]C4 | Cross-sectional (small HH sub-group) |
Clinical Presentation
- ▸Fatigue and arthralgias are most common symptoms; classic triad is rare.
- ▸Ferritin >1000 ng/mL is strongest predictor of cirrhosis (OR 15.6).
Many patients remain asymptomatic for decades; classic triad (bronze diabetes, cirrhosis, cardiomegaly) is now rare [67]B2b. Modern presentation: fatigue (40-75%), arthralgias (30-50%), RUQ discomfort (15-30%) [63]A1c[67]B2b. Physical exam may show bronze skin (now <10%), hepatomegaly (30-60%), testicular atrophy (10-20%), and arthropathy of 2nd/3rd MCP joints (40-65%) [63]A1c[67]B2b. Red flags: ascites, jaundice, variceal bleeding, encephalopathy → advanced cirrhosis; new dyspnea, S3 gallop → cardiac involvement; orthostatic hypotension or dysphagia → juvenile hemochromatosis [20]D5[63]A1c[65]C4[69]A1c[73]C4. Variants include HFE C282Y homozygote (80-90%), compound heterozygote (4-5%), ferroportin disease (1-3%), juvenile (rare), TfR2-related (<1%) [37]B2b[63]A1c[64]A1a[65]C4[73]C4. Atypical presentations: isolated hyperferritinemia with normal TSAT (suspect ferroportin disease or secondary overload); hepatogenous diabetes with normal fasting glucose [32]D5[37]B2b[64]A1a[71]C4. Pearl: Serum ferritin >1000 ng/mL at diagnosis is the single strongest predictor of cirrhosis (odds ratio 15.6), and its presence mandates urgent MRI for hepatic iron quantification and specialist referral for therapeutic phlebotomy [44]B2b[63]A1c[68]B2b.
| Variant | Key Features | Frequency |
|---|---|---|
| HFE C282Y homozygote | Male predominance; cirrhosis at ferritin >1000 ng/mL; classic arthropathy | 80-90% of HH in Europeans |
| HFE C282Y/H63D compound heterozygote | Milder iron overload; typically requires comorbid steatosis or alcohol | 4-5% of HH |
| Ferroportin disease (SLC40A1) | Autosomal dominant; high ferritin with normal-to-low TSAT; macrophage iron loading; mild symptoms | 1-3% of HH; more common in Asia |
| Juvenile hemochromatosis (HJV or HAMP) | Rapid progression before age 30; severe cardiomyopathy and hypogonadism; heart failure and death by age 40 if untreated | Rare; <1% of HH |
| TfR2-related HH | Similar to HFE but earlier onset; reported in Asian populations | <1% of HH; more common in Japan and Taiwan |
Diagnosis & Workup
- ▸Fasting TSAT >45% (women) or >50% (men) is earliest and most sensitive screening test.
- ▸MRI T2*/R2* relaxometry is preferred for noninvasive liver iron quantification; biopsy reserved for inconclusive cases.
Stepwise: (1) Biochemical iron studies - fasting TSAT >45% (women) or >50% (men) is most sensitive marker [63]A1c[74]A1c; elevated ferritin indicates stores but is acute-phase reactant. (2) Confirmatory genetic testing - HFE genotyping for C282Y and H63D; C282Y homozygosity accounts for >90% of HH in Northern Europeans [20]D5[33]A1c[63]A1c. If HFE-negative with high TSAT/ferritin, consider next-generation sequencing for non-HFE genes (HAMP, HJV, TFR2, SLC40A1, BMP6) [74]A1c[75]C4[79]B3b. (3) Quantifying hepatic iron - MRI T2* or R2* relaxometry is noninvasive gold standard; sensitivity 89%, specificity 88% for LIC >1.8 mg/g dry weight [76]A1a. reserved for inconclusive cases or to stage fibrosis [63]A1c[74]A1c. (4) Noninvasive fibrosis assessment - ferritin >1000 μg/L identifies high risk (NPV 98% for cirrhosis when <1000 and AST normal) [63]A1c[74]A1c[82]B2b; FIB-4 ≥2.67 has sens 70%, spec 86%; hyaluronic acid >46.5 ng/mL + ferritin >1000 μg/L gives AUROC 0.93 [82]B2b[89]B3b. (5) End-organ assessment - liver (ultrasound q6-12mo if cirrhosis), heart (echo ± cardiac MRI), pancreas (fasting glucose, HbA1c, consider OGTT), joints (clinical ± X-ray), pituitary/gonads (LH, FSH, testosterone, estradiol) [32]D5[63]A1c[74]A1c[95]B2b. Pearl: The diagnostic cornerstone is fasting TSAT and ferritin; HFE genotyping plus MRI-LIC (when needed) provides definitive diagnosis without biopsy in most patients [63]A1c[74]A1c.
| Type | Gene | TSAT | Ferritin | Key Features |
|---|---|---|---|---|
| Type 1 (HFE) | HFE (C282Y) | High | High | Most common; Northern European ancestry; late onset |
| Type 2A (Juvenile) | HJV | Very high | High | Early onset (2nd-3rd decade); cardiomyopathy, hypogonadism |
| Type 2B (Juvenile) | HAMP | Very high | High | Early onset; severe |
| Type 3 (TFR2) | TFR2 | High | High | Intermediate age onset; rare in Asians [65]C4 |
| Type 4A (Ferroportin disease) | SLC40A1 | Normal | High | Macrophage iron loading; high splenic iron; mild symptoms [37]B2b[64]A1a |
| Type 4B (Ferroportin HC) | SLC40A1 | High | High | Hepatocellular iron loading; resembles HFE type |
| Test | Cutoff | AUROC (F3-F4) | Sensitivity | Specificity | Reference |
|---|---|---|---|---|---|
| FIB-4 | ≥2.67 | 0.85 | 70% | 86% | [89]B3b |
| APRI | ≥1.0 | 0.78 | 55% | 91% | [89]B3b |
| Hyaluronic acid | >46.5 ng/mL | 0.93 (with ferritin) | 87% | 88% | [82]B2b |
Severity, Staging & Risk Stratification
- ▸Liver fibrosis stage is primary driver of prognosis.
- ▸FIB-4 >3.25 identifies advanced fibrosis with 92% specificity; noninvasive scores often obviate biopsy.
Liver fibrosis stage is the most important predictor of outcomes. Cirrhosis develops in ≈10-25% of C282Y homozygotes, especially men >40 with heavy iron loading (HIC >283 µmol/g dry weight), alcohol >60 g/day, and metabolic comorbidities [9]B3b[38]B2b. Noninvasive scores are well-validated: APRI >1.0 (AUROC 0.89) and FIB-4 >3.25 (AUROC 0.92) for F3-F4 fibrosis [89]B3b. MRI R2*/T2* can estimate HIC noninvasively [37]B2b. Prognostic scores for decompensated cirrhosis: (5-15 points; Class A 1-year survival ≥95%, Class B/C worse) and (3-month mortality, with MELD-Na and MELD 3.0 refinements) [55]C4[102]B2b. For HCC with cirrhosis, staging governs treatment and carries median survival ~11 months [102]B2b. Risk modifiers: polygenic risk scores for iron and liver disease increase risk up to 3-fold [78]B2b; GNPAT variant associated with more severe iron overload [96]B3b; alcohol doubles cirrhosis risk (OR 2.1) [9]B3b; diabetes increases fibrosis progression ~1.7-fold [98]B3b. Functional iron burden assessed by phlebotomy volume: men typically require 3-5 g iron removal, women <2 g [97]B2b. Pearl: In C282Y-homozygous hemochromatosis, liver fibrosis stage is the primary driver of prognosis, FIB-4 >3.25 identifies advanced fibrosis (F3-F4) with 92% specificity, and noninvasive scores can reliably obviate the need for liver biopsy in many patients [89]B3b.
| Score | Formula | Cut-off for F3-F4 | AUROC (95% CI) | Sensitivity | Specificity |
|---|---|---|---|---|---|
| APRI | (AST/ULN) / Platelets (10⁹/L) × 100 | >1.0 | 0.89 (0.84-0.95) | 0.74 | 0.90 |
| FIB-4 | (Age × AST) / (Platelets × √ALT) | >3.25 | 0.92 (0.89-0.97) | 0.81 | 0.92 |
Acute Management & Decompensation Events
- ▸Phlebotomy must be paused during acute decompensation until hemodynamically stable.
- ▸Decompensation events managed as per standard cirrhosis guidelines, with caution for cardiac iron overload.
Established cirrhosis carries same decompensation risks (variceal hemorrhage, SBP, HE, HRS-AKI) as other etiologies, but iron toxicity may accelerate deterioration. Phlebotomy must be paused during any acute episode until hemodynamically stable [63]A1c[74]A1c. Variceal hemorrhage: urgent within 12h, EVL + vasoactive drug (terlipressin 2 mg IV q4h or octreotide 50 µg IV bolus then 50 µg/h for 3-5 days) + antibiotic prophylaxis ( 1 g IV daily × 5-7 days) [74]A1c[110]D5. Rescue with TIPS if EVL fails. Target Hb 7-9 g/dL [110]D5. SBP: ascitic fluid PMN ≥250/µL → start empiric 2 g IV q8h or 2 g IV daily × 5 days; albumin 1.5 g/kg day 1, 1 g/kg day 3 if Cr >1 or bili >4 [110]D5. HE: lactulose (20-30 g PO/NG q1-2h until 2-3 loose stools, then titrate) ± rifaximin 550 mg PO BID; check ferritin/TSAT [110]D5. HRS-AKI: terlipressin 0.5-1 mg IV q4-6h + albumin 20-40 g IV daily for 7-14 days [110]D5; consider echocardiography/cardiac MRI T2* before aggressive fluid resuscitation to avoid heart failure from iron cardiomyopathy [37]B2b. Resumption of phlebotomy: wait ≥1 week after acute event, resume at half volume (250 mL), target ferritin 50-100 µg/L, TSAT <50% [63]A1c[74]A1c. Pearl: Decompensated hemochromatosis cirrhosis is managed identically to other cirrhosis etiologies, but phlebotomy must be paused during acute events; cardiac MRI T2* should be considered before aggressive fluid resuscitation to avoid precipitating heart failure from co-existing cardiac siderosis [37]B2b[74]A1c.
| Decompensation | First-line therapy | Drug of choice (dose) | Adjunctive therapy | Duration |
|---|---|---|---|---|
| Variceal hemorrhage | EVL + vasoactive drug | Terlipressin 2 mg IV q4h (or octreotide 50 μg bolus + 50 μg/h) | Ceftriaxone 1 g IV × 5-7 d; target Hb 7-9 | 3-5 d (vasoactive) |
| SBP | Cefotaxime 2 g IV q8h | Cefotaxime (or ceftriaxone 2 g IV daily) | Albumin 1.5 g/kg d1 + 1 g/kg d3 (if high-risk) | 5 d |
| Hepatic encephalopathy | Lactulose | Lactulose 20-30 g q1-2h titrated to 2-3 soft stools | Rifaximin 550 mg PO BID for recurrent HE | Until clinical resolution |
| HRS-AKI | Terlipressin + albumin | Terlipressin 0.5-1 mg IV q4-6h; albumin 20-40 g IV daily | Consider TIPS if no response after 7 d | 7-14 d |
Long-term & Definitive Management
- ▸Maintenance goal: ferritin 50-100 µg/L and TSAT <50%.
- ▸Lifelong HCC surveillance for prior cirrhosis; add PPI to reduce phlebotomy need.
Goal: maintain ferritin 50-100 µg/L and TSAT <50% [74]A1c[106]B2b. Maintenance phlebotomy typically q2-4 months lifelong. Adjunctive therapy: pantoprazole 40 mg/day reduces phlebotomy frequency by ~33-50% [113]A1b[120]B3b. Iron chelation (deferasirox 10-20 mg/kg/day) is second-line for those intolerant to phlebotomy, but contraindicated in Child-Pugh B/C cirrhosis [63]A1c[74]A1c[117]B2b. Surveillance schedule: abdominal ultrasound q6mo for HCC if F3/F4 fibrosis (even if regresses) [74]A1c[91]B3b; fasting glucose + HbA1c annually; clinical assessment for arthropathy annually; echocardiogram q3-5 years if TSAT >50% or severe overload; DXA at diagnosis if cirrhosis, repeat q2-3yr if osteopenia [39]D5[55]C4[63]A1c[74]A1c. First-degree relatives of C282Y homozygote: offer HFE genotyping and iron studies (1 in 4 risk for siblings) [74]A1c[63]A1c[48]B2b. Do not supplement iron or vitamin C; do not perform routine phlebotomy in severe cardiomyopathy or decompensated cirrhosis; do not use deferasirox in Child-Pugh B/C; do not use interferon for HCV without first depleting iron [20]D5[25]D5[74]A1c[117]B2b. Pearl: The lifelong goal is ferritin 50-100 μg/L AND TSAT <50%; add a PPI (pantoprazole 40 mg/day) to reduce phlebotomy frequency, and never stop HCC surveillance in patients with a prior diagnosis of cirrhosis, even if fibrosis appears to regress [74]A1c[91]B3b[113]A1b.
| Target complication | Surveillance method | Frequency | Threshold for action / notes | Evidence |
|---|---|---|---|---|
| Cirrhosis / HCC | Abdominal ultrasound (± AFP) every 6 months | Every 6 months | Start only in patients with F3/F4 fibrosis (or indeterminate by noninvasive tests). High-risk population: men with ferritin >1000 μg/L at diagnosis [74]A1c (1c) [63]A1c (1c). | |
| Diabetes mellitus | Fasting glucose, HbA1c annually | Annually | Early detection of glucose intolerance; oral glucose tolerance test if fasting glucose is normal but clinical suspicion is high (e.g., obesity, family history) [32]D5 (5). | |
| Arthropathy | Clinical assessment for joint pain, swelling, and early morning stiffness | Annually | Iron-induced arthropathy (typically second and third MCP joints) is often irreversible despite iron depletion; symptomatic management with NSAIDs or intra-articular steroids [94]D5 (5). | |
| Cardiomyopathy | Echocardiogram, ± cardiac MRI for iron quantification | Every 3-5 years (or earlier if symptoms develop) | Consider if TSAT >50% despite normal ferritin, or in patients with severe iron overload at diagnosis. Cardiac iron deposition is rare in HFE hemochromatosis but life-threatening when present [63]A1c (1c). | |
| Osteoporosis | Bone mineral density (DXA) scan | At diagnosis in patients with cirrhosis; repeat every 2-3 years if osteopenia | Hemochromatosis patients with cirrhosis or longstanding iron overload are at increased risk; calcium and vitamin D supplementation as needed [39]D5 (5), [55]C4 (4). |
Decompensation & Transplant Management
- ▸Liver transplantation cures hepatic iron defect; 5-year survival ~77.5%.
- ▸Pre-transplant cardiac MRI T2* mandatory; treat myocardial iron loading before listing.
Decompensation management follows standard cirrhosis care, with awareness of coexisting cardiac iron deposition. Ascites: Na restriction <2g/day, spironolactone 100 mg PO daily (max 400 mg) ± furosemide 40 mg daily; refractory: LVP + albumin 8g/L if >5L drained; TIPS for diuretic-refractory, but pre-TIPS echo to rule out iron cardiomyopathy [29]C4. Variceal hemorrhage: urgent EVL + terlipressin (2 mg IV q4h) or octreotide, + ceftriaxone 1 g IV daily × 5-7 days [110]D5. HRS-AKI: terlipressin (0.85-1 mg IV q4-6h) + albumin (1 g/kg day 1, then 20-40 g/day) for 7-14 days [29]C4[110]D5. Liver transplantation indicated for decompensated cirrhosis (Child-Pugh B/C, MELD ≥15) or early HCC (Milan criteria). Absolute contraindications: active extrahepatic malignancy, uncontrolled sepsis, severe pulmonary hypertension (mean PAP >45 mmHg), advanced cardiopulmonary disease [46]D5[125]D5. Pre-transplant cardiac MRI T2* to quantify myocardial iron (T2* <20 ms indicates loading); intensive phlebotomy or chelation (deferoxamine 20-40 mg/kg/day IV/SC) for 3-6 months prior to listing [12]B2b[125]D5. Post-LT survival: 88.7% at 1 year, 77.5% at 5 years, comparable to other CLD [49]B2b. LT cures hepatic defect (hepcidin normalizes); no systematic phlebotomy needed, but monitor ferritin and TSAT annually [12]B2b[69]A1c. Post-LT cardiac MRI at 6 and 12 months [125]D5. Maintain standard immunosuppression (tacrolimus or cyclosporine + mycophenolate); bone health: vitamin D 800 IU/day, calcium 1000-1200 mg/day, bisphosphonate if T-score ≤ -2.5 [39]D5. Pearl: Liver transplantation cures HFE hemochromatosis by restoring normal hepcidin production, achieving 5-year survival rates exceeding 77%, but requires aggressive pre-transplant cardiac iron reduction (MRI T2* ≤20 ms) and lifelong post-transplant surveillance for extrahepatic iron progression [12]B2b[49]B2b[125]D5.
| Modality | Indication | Key regimen | Outcome | Evidence level |
|---|---|---|---|---|
| Liver transplant | Decompensated cirrhosis, early HCC | Deceased-donor or living-donor LT | 5-year survival 77.5% (95% CI 72.8-81.4%) | 2b [49]B2b |
| Phlebotomy | Pre-transplant iron reduction | 1 unit (400-500 mL) every 1-2 weeks until ferritin <50 ng/mL | Reduces myocardial iron | 4 [12]B2b |
| Deferoxamine | Pre-transplant chelation | 20-40 mg/kg/day IV/SC over 8-12 h | Accelerates iron removal | 4 [12]B2b |
| Bisphosphonate | Post-transplant osteoporosis | Alendronate 70 mg weekly | Prevents fractures | 5 [39]D5 |
| Terlipressin | HRS-AKI | 1 mg IV q4h + albumin | Improves renal function | 2b [29]C4 |
| TIPS | Refractory ascites | 8-10 mm covered stent | Reduces ascites | 4 [29]C4 |
Complications: The Systemic Consequences of Iron Overload
- ▸Cirrhosis in 25-30% men; HCC incidence 1-2%/y in cirrhotics.
- ▸Arthropathy (40-60%) is most common non-hepatic complication and does not reverse with phlebotomy.
Untreated hemochromatosis leads to multi-organ damage via oxidative stress and fibrogenesis [74]A1c. Hepatic: cirrhosis (25-30% men, 10-15% women) [74]A1c[134]B2b; HCC (annual incidence 1-2% in cirrhotics; OR 11 vs wild-type) [131]A1a; phlebotomy can reverse F3 fibrosis (85%) and some F4 (30%) [80]C4. Metabolic/endocrine: diabetes (15-30%), hepatogenous, partially reversible [32]D5[38]B2b[134]B2b; hypogonadotropic hypogonadism (10-40% men) [60]D5. Cardiac: dilated cardiomyopathy (5-15%), arrhythmias; major predictor of mortality [25]D5[47]B2b. Musculoskeletal: arthropathy (40-60%), often irreversible, involving 2nd/3rd MCP joints, chondrocalcinosis [74]A1c[134]B2b. Infections: HR 1.24 for any hospitalization with infection; increased risk with Yersinia enterocolitica, Vibrio vulnificus [135]B2b. Vaccinate against Hep A and B [3]B2b. Malignancy: extrahepatic cancers (colorectal OR 1.29, breast OR 1.29) but not increased in treated patients [51]B2b[57]A1a. Fertility: reduced in both sexes; optimize iron status pre-conception; phlebotomy safe in pregnancy, chelation contraindicated [60]D5. Pearl: The hallmarks of untreated hemochromatosis, cirrhosis (25-30% of men), HCC (annual incidence 1-2% in cirrhotic patients), diabetes (15-30%), and arthropathy (40-60%), are largely preventable if iron depletion is initiated before fibrosis develops [74]A1c[134]B2b; even established cirrhosis can regress in one-third of patients with aggressive phlebotomy [80]C4.
| Complication | Frequency in C282Y Homozygotes | Prevention | Management |
|---|---|---|---|
| Cirrhosis | 25-30% (men), 10-15% (women) [74]A1c[134]B2b | Early phlebotomy, avoid alcohol, manage obesity | Phlebotomy to ferritin <50 μg/L; HCC surveillance if cirrhosis established [74]A1c |
| HCC | Annual incidence ~1-2% in cirrhotic patients; OR 11 vs. wild-type [131]A1a | Iron depletion; ultrasound + AFP every 6 months | Surgical resection, locoregional therapy, or LT per BCLC; 5-year post-LT survival ~78% [49]B2b[136]C4 |
| Diabetes mellitus | 15-30% at diagnosis [38]B2b[134]B2b | Phlebotomy may improve but not fully reverse | Metformin first-line; OGTT more sensitive than HbA1c [32]D5[74]A1c |
| Cardiomyopathy | 5-15% [25]D5 | Phlebotomy to maintain normal iron stores | TTE at diagnosis (or MRI T2*); chelation if severe [25]D5 |
| Arthropathy | 40-60% [74]A1c[134]B2b | Not preventable by phlebotomy once established | Analgesics, IA steroids, arthroplasty [74]A1c |
| Hypogonadotropic hypogonadism | 10-40% in men [60]D5 | Phlebotomy | Testosterone replacement; bone density monitoring [60]D5 |
| Infections (including siderophilic organisms) | HR 1.24 for serious infections [135]B2b | Vaccination; avoid raw shellfish/ unpasteurized dairy | Prompt culture-directed antibiotics; consider chelation [59]D5[135]B2b |
Prognosis & Natural History
- ▸Ferritin >1000 µg/L marks critical inflection point for morbidity/mortality.
- ▸Early diagnosis and phlebotomy normalize survival; cirrhosis reduces 5-year survival to 60-70%.
Untreated hemochromatosis follows silent iron loading for decades, then organ injury. Symptoms rare before age 40 in men, after menopause in women [33]A1c[137]B2b. Critical inflection: ferritin >1000 µg/L → sharp increase in cirrhosis, diabetes, cardiomyopathy [90]B2b. Among patients with ferritin >1000 at diagnosis, iron overload-associated mortality 18.7% vs <1% below threshold (HR 5.6; NNT=6) [90]B2b. Once cirrhosis develops, annual HCC risk 1-2% [91]B3b. Survival: diagnosed before cirrhosis → 5-year survival 95-98% (normal) [47]B2b; diagnosed with ferritin >1000 µg/L → 5-year 78-85% [90]B2b; diagnosed with cirrhosis → 5-year 60-70% [91]B3b. Post-transplant 5-year survival 77.5% [49]B2b. Modifiers: male sex (2-3:1 ratio), alcohol (>60g/day, OR 4.5 for cirrhosis) [38]B2b, metabolic comorbidities, genetic modifiers (GNPAT, TMPRSS6, PNPLA3) [78]B2b. Phlebotomy reduces excess mortality but does not eliminate if cirrhosis present; treated non-cirrhotics have no excess mortality (SMR 0.99) [47]B2b. Pearl: Patients diagnosed and treated before cirrhosis develops have survival indistinguishable from the general population (standardized mortality ratio 1.0, 95% CI 0.7-1.4) [47]B2b.
| Population | 5-Year Survival | 10-Year Survival | Key Determinants |
|---|---|---|---|
| C282Y homozygotes diagnosed before development of cirrhosis or diabetes | 95-98% (approaching general population) | 93-95% | Female sex, low ferritin at diagnosis, absence of metabolic comorbidities [47]B2b[48]B2b |
| C282Y homozygotes with ferritin > 1000 μg/L at diagnosis | 78-85% | 65-72% | Male sex,饮酒 > 60 g/day, viral hepatitis co-infection [38]B2b[90]B2b |
| C282Y homozygotes with cirrhosis at diagnosis | 60-70% | 45-55% | HCC develops in 20-30% within 10 years [91]B3b |
| Patients undergoing liver transplantation for HH | 77.5% at 5 years (95% CI 72.8-81.4%) | Not routinely reported beyond 5 years | Outcomes similar to propensity-matched CLD controls in modern era (2003-2019) [49]B2b |
Special Populations & Prevention
- ▸Suspend phlebotomy during pregnancy; resume 6-8 weeks postpartum.
- ▸Vaccinate for hepatitis A/B; cascade screen first-degree relatives.
Pregnancy: phlebotomy suspended during pregnancy; resume 6-8 weeks postpartum [33]A1c[74]A1c. Neonatal hemochromatosis (NH) is distinct (gestational alloimmune liver disease, GALD), not HFE-related [99]B2a. Pediatrics: rare; if hyperferritinemia, exclude hereditary hyperferritinemia-cataract syndrome (HHCS) by TSAT (normal in HHCS) [141]C4. Phlebotomy dose: 5 mL/kg (max 250 mL) weekly, target ferritin <50 μg/L [74]A1c. Monitor growth, puberty, gonadal function [60]D5. Elderly: often advanced fibrosis at diagnosis; phlebotomy 250-300 mL q2wk, maintain Hb >11 g/dL; MR R2 relaxometry preferred for LIC [33]A1c[56]C4[85]B2b. Immunocompromised/Renal/Cardiac: CKD accelerates myocardial iron; chelation (deferasirox 10-20 mg/kg/day) may be needed if eGFR <30 [25]D5. American Heart Association classifies HH as risk factor for heart failure; cardiac MRI T2* recommended [142]D5. Prevention: vaccinate all patients with elevated ferritin and liver fibrosis against hepatitis A (Havrix 1440 ELU, 2 doses 6-12mo apart) and B (Engerix-B 20 μg, 3 doses) [3]B2b. Cascade screening of first-degree relatives (HFE genotyping + iron studies) is cost-effective [97]B2b[107]A1a[140]B2b. Genetic counseling about incomplete penetrance (~20% males, ~5% females) [78]B2b. Pearl: Phlebotomy should be suspended during pregnancy; neonatal hemochromatosis is a distinct alloimmune disorder not linked to HFE, and pediatric hereditary hemochromatosis is rare, when children present with hyperferritinemia, first exclude HHCS by measuring TSAT [74]A1c[141]C4.
| Feature | HFE Hemochromatosis | HHCS [141]C4 |
|---|---|---|
| Inheritance | Autosomal recessive (HFE) | Autosomal dominant (FTL) |
| Serum ferritin | Elevated | Elevated (often very high) |
| Transferrin saturation | Elevated (>45% males, >45% females) | Normal |
| Iron overload | Yes | No |
| Pediatric cataract | No | Yes (bilateral, early onset) |
| Treatment | Phlebotomy | None (unnecessary) |
References
- [1]
Pennell DJ, Udelson JE, Arai AE et al.. “Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.” Circulation (2013). PMID: 23775258 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature - [2]
Morisco F, Pagliaro L, Caporaso N et al.. “Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2008). PMID: 18395501 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature - [3]
Meza-Torres B, Forbes A, Elson W et al.. “Hepatitis A Vaccination Coverage Among People With Chronic Liver Disease in England (HEALD): Protocol for a Retrospective Cohort Study.” JMIR research protocols (2023). PMID: 37874614 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Complications, Prognosis & Natural History, Special Populations & Prevention - [4]
Girelli D, Busti F, Brissot P et al.. “Hemochromatosis classification: update and recommendations by the BIOIRON Society.” Blood (2022). PMID: 34601591 ↗
L5OTHERCited in: Definition, Classification & Nomenclature - [5]
Lefkowitch JH. “Hepatobiliary pathology.” Current opinion in gastroenterology (2006). PMID: 16550033 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature - [6]
Del Poggio P, Mazzoleni M. “Screening in liver disease.” World journal of gastroenterology (2006). PMID: 16981254 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature - [7]
Griffiths WJ, Mayr R, McFarlane I et al.. “Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation.” Hepatology (Baltimore, Md.) (2010). PMID: 19937651 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Clinical Presentation, Long-term & Definitive Management - [8]
Vecchi C, Montosi G, Pietrangelo A. “Huh-7: a human "hemochromatotic" cell line.” Hepatology (Baltimore, Md.) (2010). PMID: 20017200 ↗
L4OTHERCited in: Pathophysiology & Mechanism - [9]
Wood MJ, Powell LW, Dixon JL et al.. “Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus.” Hepatology (Baltimore, Md.) (2012). PMID: 22422567 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events - [10]
Wang H, An P, Xie E et al.. “Characterization of ferroptosis in murine models of hemochromatosis.” Hepatology (Baltimore, Md.) (2017). PMID: 28195347 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management - [11]
Olynyk JK, Trinder D, Ramm GA et al.. “Hereditary hemochromatosis in the post-HFE era.” Hepatology (Baltimore, Md.) (2008). PMID: 18752323 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [12]
Bardou-Jacquet E, Philip J, Lorho R et al.. “Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis.” Hepatology (Baltimore, Md.) (2014). PMID: 23775519 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Decompensation & Transplant Management, Complications, Prognosis & Natural History - [13]
Wood MJ, Gadd VL, Powell LW et al.. “Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression.” Hepatology (Baltimore, Md.) (2014). PMID: 24037895 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [14]
Tirnitz-Parker JE, Viebahn CS, Jakubowski A et al.. “Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells.” Hepatology (Baltimore, Md.) (2010). PMID: 20578156 ↗
L4OTHERCited in: Pathophysiology & Mechanism - [15]
Gautheron J, Gores GJ, Rodrigues CMP. “Lytic cell death in metabolic liver disease.” Journal of hepatology (2020). PMID: 32298766 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [16]
Baffy G, Brunt EM, Caldwell SH. “Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.” Journal of hepatology (2012). PMID: 22326465 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Complications, Prognosis & Natural History, Special Populations & Prevention - [17]
Barisani D, Pelucchi S, Mariani R et al.. “Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload.” Journal of hepatology (2008). PMID: 18462824 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [18]
Lunova M, Goehring C, Kuscuoglu D et al.. “Hepcidin knockout mice fed with iron-rich diet develop chronic liver injury and liver fibrosis due to lysosomal iron overload.” Journal of hepatology (2014). PMID: 24816174 ↗
L4OTHERCited in: Pathophysiology & Mechanism - [19]
Aigner E, Strasser M, Haufe H et al.. “A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.” The American journal of gastroenterology (2010). PMID: 20407430 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [20]
Pietrangelo A. “Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.” Gastroenterology (2010). PMID: 20542038 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management - [21]
Pietrangelo A. “Genetics, Genetic Testing, and Management of Hemochromatosis: 15 Years Since Hepcidin.” Gastroenterology (2015). PMID: 26164493 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management - [22]
Garuti C, Tian Y, Montosi G et al.. “Hepcidin expression does not rescue the iron-poor phenotype of Kupffer cells in Hfe-null mice after liver transplantation.” Gastroenterology (2010). PMID: 20338170 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Decompensation & Transplant Management - [23]
Corradini E, Schmidt PJ, Meynard D et al.. “BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice.” Gastroenterology (2010). PMID: 20682319 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management - [24]
Akbarialiabad H, Jamshidi P, Callen JP et al.. “Dermatologic manifestations of hereditary hemochromatosis: A systematic review.” Journal of the European Academy of Dermatology and Venereology : JEADV (2024). PMID: 38752605 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events - [25]
Siddique A, Kowdley KV. “Review article: the iron overload syndromes.” Alimentary pharmacology & therapeutics (2012). PMID: 22385471 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Complications, Prognosis & Natural History, Special Populations & Prevention - [26]
Ruban Agarvas A, Sparla R, Atkins JL et al.. “Ferritin and transferrin predict common carotid intima-media thickness in females: a machine-learning informed individual participant data meta-analysis.” BMC cardiovascular disorders (2026). PMID: 41981480 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [27]
Parker CN, Finlayson KJ, Hall EJ et al.. “Exploring the Association between Hemochromatosis and Lower-Limb Venous Disease.” Advances in skin & wound care (2024). PMID: 38117169 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism - [28]
Scribner C, Cope J, Ryan P et al.. “A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload.” Scientific reports (2025). PMID: 40382392 ↗
L1RCTCited in: Pathophysiology & Mechanism - [29]
Tie J, Jia WY, Gou X. “Portal Hypertension Refractory Ascites Caused by Secondary Hemochromatosis.” Journal of clinical and translational hepatology (2023). PMID: 37408812 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Decompensation & Transplant Management - [30]
Buianova AA, Gaydina TA, Reznik EV et al.. “A case of mixed histiocytosis (Erdheim-Chester disease and Langerhans cell histiocytosis) with STEAP3-associated anemia and type 4 hemochromatosis.” Orphanet journal of rare diseases (2026). PMID: 42116186 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Prognosis & Natural History - [31]
D'Onofrio V, Esposito FM, Marra R et al.. “Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrum.” Blood advances (2026). PMID: 42018644 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Prognosis & Natural History - [32]
El-Azab G, Rady MA, Assem M et al.. “Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions.” Clinical and experimental medicine (2026). PMID: 42001361 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Prognosis & Natural History - [33]
. “EASL clinical practice guidelines for HFE hemochromatosis.” Journal of hepatology (2010). PMID: 20471131 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Prognosis & Natural History, Special Populations & Prevention - [34]
Kwo PY, Cohen SM, Lim JK. “ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.” The American journal of gastroenterology (2016). PMID: 27995906 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications, Prognosis & Natural History, Special Populations & Prevention - [35]
Hernaez R, Yeung E, Clark JM et al.. “Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis.” Journal of hepatology (2011). PMID: 21354231 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [36]
Timpani G, Foti F, Nicolò A et al.. “Is exchange transfusion a possible treatment for neonatal hemochromatosis?” Journal of hepatology (2007). PMID: 17869371 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Decompensation & Transplant Management, Prognosis & Natural History - [37]
Troppmair MR, Ricci A, Scarlini S et al.. “Characterization of ferroportin disease and SLC40A1-related hemochromatosis - Results from the EASL non-HFE registry.” Journal of hepatology (2025). PMID: 41855270 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management - [38]
Fracanzani AL, Piperno A, Valenti L et al.. “Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors.” Hepatology (Baltimore, Md.) (2010). PMID: 20101754 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History - [39]
Collier J. “Bone disorders in chronic liver disease.” Hepatology (Baltimore, Md.) (2007). PMID: 17886334 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Decompensation & Transplant Management - [40]
Winters AC, Tremblay D, Arinsburg S et al.. “Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis.” Hepatology (Baltimore, Md.) (2018). PMID: 28902419 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Complications - [41]
Gurrin LC, Bertalli NA, Dalton GW et al.. “HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity.” Hepatology (Baltimore, Md.) (2009). PMID: 19554541 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [42]
Lucas MR, Pilling LC, Atkins JL et al.. “Incidence of liver complications with hemochromatosis-associated HFE p.C282Y homozygosity: The role of central adiposity.” Hepatology (Baltimore, Md.) (2024). PMID: 39178373 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [43]
Welzel TM, Graubard BI, Zeuzem S et al.. “Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.” Hepatology (Baltimore, Md.) (2011). PMID: 21538440 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications - [44]
Allen KJ, Bertalli NA, Osborne NJ et al.. “HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis.” Hepatology (Baltimore, Md.) (2010). PMID: 20583211 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management & Decompensation Events - [45]
Valenti L, Fracanzani AL, Rametta R et al.. “Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis.” Journal of hepatology (2012). PMID: 22885719 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications - [46]
Fagiuoli S, Daina E, D'Antiga L et al.. “Monogenic diseases that can be cured by liver transplantation.” Journal of hepatology (2013). PMID: 23578885 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Decompensation & Transplant Management, Complications, Prognosis & Natural History - [47]
Bardou-Jacquet E, Morcet J, Manet G et al.. “Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis.” Journal of hepatology (2014). PMID: 25450707 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Prognosis & Natural History - [48]
Elmberg M, Hultcrantz R, Ebrahim F et al.. “Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives.” Gastroenterology (2009). PMID: 19622361 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Prognosis & Natural History - [49]
Lymberopoulos P, Prakash S, Shaikh A et al.. “Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2022). PMID: 35770428 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Decompensation & Transplant Management, Complications, Prognosis & Natural History - [50]
Adams PC, Ryan JD. “Diagnosis and Treatment of Hemochromatosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 39889898 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Complications, Prognosis & Natural History - [51]
Crum-Cianflone N, Collins G, Medina S et al.. “Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19800985 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Complications, Prognosis & Natural History - [52]
Olynyk JK, Gan E, Tan T. “Predicting iron overload in hyperferritinemia.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 19095082 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors - [53]
Murray JA, McLachlan S, Adams PC et al.. “Association between celiac disease and iron deficiency in Caucasians, but not non-Caucasians.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23416278 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention - [54]
Walsh A, Dixon JL, Ramm GA et al.. “The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2006). PMID: 16979952 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Special Populations & Prevention - [55]
Fisher L, Fisher A. “Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17222588 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management - [56]
Beaton M, Adams PC. “Assessment of silent liver fibrosis in hemochromatosis C282Y homozygotes with normal transaminase levels.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18550006 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations & Prevention - [57]
Buttignol M, Bouche C, Chrétien M et al.. “Hemochromatosis: A Risk Factor for Breast Cancer? Systematic Review and Meta-Analysis.” European journal of breast health (2025). PMID: 40910550 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications, Prognosis & Natural History - [58]
Packer M, Butler J, Ho JE et al.. “What Are HFpEF Mimics and What Are They Mimicking? Insights Into Our Conceptualization of Heart Failure With Preserved Ejection Fraction as a Disease.” Journal of cardiac failure (2026). PMID: 42314825 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [59]
Das S, Majumder S, Saqib M et al.. “Expansion of CD101⁻ neutrophils drives susceptibility to hyperyersiniabactin-producing Yersinia infection in hereditary hemochromatotic hosts.” Infection and immunity (2026). PMID: 42283579 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History - [60]
Carlomagno F, Tenuta M, Sansone A et al.. “Iron overload disorders in adults: a comprehensive review of gonadal function, reproductive, and sexual health.” Human reproduction update (2026). PMID: 42101252 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Special Populations & Prevention - [61]
Toivonen J, Clancy J, Åberg F et al.. “Quantifying risk modifiers of hereditary hemochromatosis using genomic and electronic health record data.” JHEP reports : innovation in hepatology (2026). PMID: 41861673 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Special Populations & Prevention - [62]
Taya R, Tantiworawit A, Thongwitokomarn H et al.. “Severe bacterial infection in thalassemia patients: prevalence, predisposing factors, causative organisms and outcomes.” Frontiers in medicine (2026). PMID: 41788721 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [63]
Kowdley KV, Brown KE, Ahn J et al.. “ACG Clinical Guideline: Hereditary Hemochromatosis.” The American journal of gastroenterology (2019). PMID: 31335359 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management - [64]
Mayr R, Janecke AR, Schranz M et al.. “Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.” Journal of hepatology (2010). PMID: 20691492 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup - [65]
Hsiao PJ, Tsai KB, Shin SJ et al.. “A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis.” Journal of hepatology (2007). PMID: 17562347 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup - [66]
de Tayrac M, Roth MP, Jouanolle AM et al.. “Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis.” Journal of hepatology (2014). PMID: 25457201 ↗
L2OTHERCited in: Clinical Presentation - [67]
Deugnier Y, Morcet J, Lainé F et al.. “Reduced phenotypic expression in genetic hemochromatosis with time: Role of exposure to non-genetic modifiers.” Journal of hepatology (2018). PMID: 30244162 ↗
L2OTHERCited in: Clinical Presentation - [68]
Adams PC, Passmore L, Chakrabarti S et al.. “Liver diseases in the hemochromatosis and iron overload screening study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2006). PMID: 16797244 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Special Populations & Prevention - [69]
. “[Chinese guidelines for the diagnosis and treatment of hereditary hemochromatosis].” Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology (2024). PMID: 39375100 ↗
L1GUIDELINECited in: Clinical Presentation, Decompensation & Transplant Management - [70]
Al Atrash E, Azaz A, Said S et al.. “Unique presentation of neonatal liver failure: A case report.” World journal of clinical pediatrics (2024). PMID: 38947999 ↗
L4CASE_REPORTCited in: Clinical Presentation - [71]
Keung Chan K, Yamaguchi DK, Treger RS et al.. “Unraveling the unexpected: Interference in iron assay leads to diagnosis of multiple myeloma.” Clinica chimica acta; international journal of clinical chemistry (2024). PMID: 38825058 ↗
L4CASE_REPORTCited in: Clinical Presentation - [72]
Elhani I, Pillebout E, Terrier B et al.. “IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients.” The Journal of rheumatology (2020). PMID: 32801133 ↗
L4CASE_REPORTCited in: Clinical Presentation - [73]
Cristancho LCQ, Urbano MA, Nati-Castillo HA et al.. “A decade of iron overload disorders and hemochromatosis: clinical and genetic findings from a specialized center in Colombia.” Frontiers in medicine (2024). PMID: 39720661 ↗
L4OTHERCited in: Clinical Presentation - [74]
. “EASL Clinical Practice Guidelines on haemochromatosis.” Journal of hepatology (2022). PMID: 35662478 ↗
L1GUIDELINECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Special Populations & Prevention - [75]
McDonald CJ, Ostini L, Wallace DF et al.. “Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders.” Journal of hepatology (2015). PMID: 26151776 ↗
L4CASE_REPORTCited in: Diagnosis & Workup - [76]
Sarigianni M, Liakos A, Vlachaki E et al.. “Accuracy of magnetic resonance imaging in diagnosis of liver iron overload: a systematic review and meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014). PMID: 24993364 ↗
L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management, Prognosis & Natural History - [77]
Pietrangelo A. “Hemochromatosis: an endocrine liver disease.” Hepatology (Baltimore, Md.) (2007). PMID: 17886335 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management - [78]
Pilling LC, Atkins JL, Melzer D. “Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort.” Hepatology (Baltimore, Md.) (2022). PMID: 35567766 ↗
L2OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Prognosis & Natural History, Special Populations & Prevention - [79]
Viveiros A, Schaefer B, Panzer M et al.. “MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes.” Hepatology (Baltimore, Md.) (2021). PMID: 34048062 ↗
L3OTHERCited in: Diagnosis & Workup - [80]
Falize L, Guillygomarc'h A, Perrin M et al.. “Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.” Hepatology (Baltimore, Md.) (2006). PMID: 16871557 ↗
L4OTHERCited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications, Special Populations & Prevention - [81]
Adams PC, Speechley M, Barton JC et al.. “Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the hemochromatosis and iron overload screening study.” Hepatology (Baltimore, Md.) (2012). PMID: 22183642 ↗
L2OTHERCited in: Diagnosis & Workup, Special Populations & Prevention - [82]
Crawford DH, Murphy TL, Ramm LE et al.. “Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis.” Hepatology (Baltimore, Md.) (2009). PMID: 19177571 ↗
L2OTHERCited in: Diagnosis & Workup, Acute Management & Decompensation Events - [83]
Hagist S, Sültmann H, Millonig G et al.. “In vitro-targeted gene identification in patients with hepatitis C using a genome-wide microarray technology.” Hepatology (Baltimore, Md.) (2009). PMID: 19177570 ↗
L4OTHERCited in: Diagnosis & Workup - [84]
Desgrippes R, Lainé F, Morcet J et al.. “Decreased iron burden in overweight C282Y homozygous women: Putative role of increased hepcidin production.” Hepatology (Baltimore, Md.) (2013). PMID: 23322654 ↗
L2OTHERCited in: Diagnosis & Workup - [85]
Mueller J, Raisi H, Rausch V et al.. “Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer.” Journal of hepatology (2017). PMID: 28483679 ↗
L2OTHERCited in: Diagnosis & Workup, Prognosis & Natural History, Special Populations & Prevention - [86]
Kono S, Suzuki H, Takahashi K et al.. “Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia.” Gastroenterology (2006). PMID: 16831606 ↗
L4CASE_REPORTCited in: Diagnosis & Workup - [87]
Valenti L, Fracanzani AL, Bugianesi E et al.. “HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.” Gastroenterology (2009). PMID: 19931264 ↗
L3OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification - [88]
Daher R, Kannengiesser C, Houamel D et al.. “Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans.” Gastroenterology (2015). PMID: 26582087 ↗
L3OTHERCited in: Diagnosis & Workup - [89]
Chin J, Powell LW, Ramm LE et al.. “Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32745684 ↗
L3OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management - [90]
Barton JC, Barton JC, Acton RT et al.. “Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 22265917 ↗
L2OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management, Prognosis & Natural History - [91]
Bardou-Jacquet E, Morandeau E, Anderson GJ et al.. “Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31622736 ↗
L3OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management, Complications, Prognosis & Natural History - [92]
Veiga-Canuto D, Miserachs M, Siddiqui I et al.. “Utility of multi-echo MRI for differentiating neonatal hemochromatosis from other causes of neonatal liver failure.” European radiology (2026). PMID: 42050293 ↗
L3OTHERCited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management - [93]
Morel P, Silva Rodriguez M, Benmouffek C et al.. “Clinical Exome Sequencing in Unexplained Hyperferritinemia Reveals Digenic and Oligogenic Inheritance Beyond Iron Homeostasis.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41968586 ↗
L3OTHERCited in: Diagnosis & Workup - [94]
Yang Y, Zu Z, Huang Y. “Hemochromatosis osteoarthritis.” Frontiers in endocrinology (2026). PMID: 41928889 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management - [95]
Hillingsø R, Kjaergaard AD, Larsen MK et al.. “C282Y Homozygosity Increases Erythrocyte Turnover and Decreases HbA1c-A Population-Based Study.” International journal of molecular sciences (2026). PMID: 41828626 ↗
L2OTHERCited in: Diagnosis & Workup, Prognosis & Natural History - [96]
McLaren CE, Emond MJ, Subramaniam VN et al.. “Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.” Hepatology (Baltimore, Md.) (2015). PMID: 25605615 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [97]
Jacobs EM, Hendriks JC, van Deursen CT et al.. “Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study.” Journal of hepatology (2008). PMID: 19008010 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History, Special Populations & Prevention - [98]
Manco M, Alisi A, Real JF et al.. “Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease.” Journal of hepatology (2010). PMID: 21168460 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [99]
Staicu A, Popa-Stanila R, Albu C et al.. “Neonatal Hemochromatosis: Systematic Review of Prenatal Ultrasound Findings-Is There a Place for MRI in the Diagnostic Process?” Journal of clinical medicine (2023). PMID: 37048762 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification, Decompensation & Transplant Management, Special Populations & Prevention - [100]
Flores-Torres J, Carver JD, Sanchez-Valle A. “PIGA Mutations Can Mimic Neonatal Hemochromatosis.” Pediatrics (2021). PMID: 33632934 ↗
L4CASE_REPORTCited in: Severity, Staging & Risk Stratification - [101]
Garcia-Malo C, Miranda C, Novo Ponte S et al.. “Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting.” Sleep medicine (2020). PMID: 32841843 ↗
L4CASE_REPORTCited in: Severity, Staging & Risk Stratification - [102]
McPhail MJW, Khorsandi SE, Abbott L et al.. “Modern Outcomes Following Treatment of Hepatocellular Carcinoma in Hereditary Hemochromatosis: A Matched Cohort Study.” American journal of clinical oncology (2019). PMID: 31436748 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification, Decompensation & Transplant Management - [103]
Xie C, Liu Y, Wang X et al.. “TFR2 p.A75V mutation aggravates liver iron overload in alcoholic liver disease via ERK pathway.” Journal of molecular medicine (Berlin, Germany) (2026). PMID: 41677839 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [104]
Preziosi ME, Singh S, Valore EV et al.. “Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload.” Journal of hepatology (2017). PMID: 28341391 ↗
L5OTHERCited in: Acute Management & Decompensation Events, Long-term & Definitive Management, Complications - [105]
McColl KE. “Effect of proton pump inhibitors on vitamins and iron.” The American journal of gastroenterology (2009). PMID: 19262546 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Long-term & Definitive Management - [106]
Bardou-Jacquet E, Lainé F, Guggenbuhl P et al.. “Worse Outcomes of Patients With HFE Hemochromatosis With Persistent Increases in Transferrin Saturation During Maintenance Therapy.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28111337 ↗
L2OTHERCited in: Acute Management & Decompensation Events, Long-term & Definitive Management, Prognosis & Natural History - [107]
Hoxha M, Malaj V, Zappacosta B. “Health Economic Evaluations of Hemochromatosis Screening and Treatment: A Systematic Review.” PharmacoEconomics - open (2024). PMID: 38279979 ↗
L1SR_OBSCited in: Acute Management & Decompensation Events, Special Populations & Prevention - [108]
Lou A, Elnenaei MO, Zhu J et al.. “Re-evaluating the utility of iron indices in hereditary hemochromatosis genotyping: A retrospective study.” Clinical biochemistry (2024). PMID: 39617311 ↗
L3COHORTCited in: Acute Management & Decompensation Events - [109]
Panzeri D, Akpinar R, D'Alfonso L et al.. “Multimodal Phasor Analysis for Digital Pathology: Quantitative Characterization of Liver Iron Overload.” Chemical & biomedical imaging (2026). PMID: 42358775 ↗
L5OTHERCited in: Acute Management & Decompensation Events, Long-term & Definitive Management - [110]
Blaney H, Waterman A, Kaplan A. “Impact of Alcohol Use on Nonalcohol-Related Liver Diseases.” Clinics in liver disease (2025). PMID: 41266012 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Decompensation & Transplant Management - [111]
Helali N, Gagnon H, Álvarez F. “Gestational alloimmune liver disease reconsidered: Advocating for a new nomenclature and enhanced diagnosis accuracy.” World journal of clinical pediatrics (2025). PMID: 41255696 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Decompensation & Transplant Management - [112]
Xu CF, Reck BH, Goodman VL et al.. “Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.” Journal of hepatology (2011). PMID: 21145803 ↗
L2RCTCited in: Long-term & Definitive Management - [113]
Vanclooster A, van Deursen C, Jaspers R et al.. “Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial.” Gastroenterology (2017). PMID: 28624580 ↗
L1RCTCited in: Long-term & Definitive Management - [114]
Valenti L, Fracanzani AL, Dongiovanni P et al.. “Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.” The American journal of gastroenterology (2007). PMID: 17391316 ↗
L3CASE_CONTROLCited in: Long-term & Definitive Management, Prognosis & Natural History - [115]
Zakhari S, Li TK. “Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease.” Hepatology (Baltimore, Md.) (2007). PMID: 18046720 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management - [116]
Colucci S, Altamura S, Marques O et al.. “Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation.” Hepatology (Baltimore, Md.) (2021). PMID: 33982327 ↗
L5OTHERCited in: Long-term & Definitive Management - [117]
Phatak P, Brissot P, Wurster M et al.. “A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.” Hepatology (Baltimore, Md.) (2010). PMID: 20814896 ↗
L2OTHERCited in: Long-term & Definitive Management - [118]
Latour C, Besson-Fournier C, Meynard D et al.. “Differing impact of the deletion of hemochromatosis-associated molecules HFE and transferrin receptor-2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin.” Hepatology (Baltimore, Md.) (2015). PMID: 26406355 ↗
L5OTHERCited in: Long-term & Definitive Management - [119]
Jolivet-Gougeon A, Loréal O, Ingels A et al.. “Serum transferrin saturation increase is associated with decrease of antibacterial activity of serum in patients with HFE-related genetic hemochromatosis.” The American journal of gastroenterology (2008). PMID: 18684194 ↗
L3OTHERCited in: Long-term & Definitive Management - [120]
van Aerts RM, van Deursen CT, Koek GH. “Proton Pump Inhibitors Reduce the Frequency of Phlebotomy in Patients With Hereditary Hemochromatosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26240005 ↗
L3OTHERCited in: Long-term & Definitive Management - [121]
Yu Y, Lu L, Fan X et al.. “Case Report: Secukinumab for the treatment of severe psoriasis in a patient with hereditary hemochromatosis.” Frontiers in medicine (2025). PMID: 40861231 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management, Complications - [122]
Colangelo L, Terracina S, Sonato C et al.. “Exploring the dynamics of FGF23 in patients with Hereditary Hemochromatosis type I following iron depletive treatment: a pilot study.” Journal of endocrinological investigation (2026). PMID: 42189479 ↗
L2OTHERCited in: Long-term & Definitive Management - [123]
Gendrot B, Peyssonnaux C, Plo I et al.. “Impaired iron balance and erythrocytosis: a complex relationship.” Blood cancer journal (2026). PMID: 42120370 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management - [124]
Lucas MR, Pilling LC, Delgado J et al.. “Liver iron levels are associated with HFE-hemochromatosis genotype, diet, adiposity, and disease in the UK Biobank.” Hepatology communications (2026). PMID: 41603411 ↗
L2OTHERCited in: Long-term & Definitive Management - [125]
Ripoll C, Yotti R, Bermejo J et al.. “The heart in liver transplantation.” Journal of hepatology (2010). PMID: 21145840 ↗
L5REVIEW_NARRATIVECited in: Decompensation & Transplant Management - [126]
Afzali A, Berry K, Ioannou GN. “Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2012). PMID: 21932374 ↗
L2OTHERCited in: Decompensation & Transplant Management, Complications, Prognosis & Natural History - [127]
Chedid MF, Zahler S, Chedid AD et al.. “Liver transplantation in the setting of a spontaneous shunt between superior mesenteric vein and right renal vein.” Annals of hepatology (2019). PMID: 31594757 ↗
L4CASE_REPORTCited in: Decompensation & Transplant Management - [128]
Xu S, Zhang P, Ge M et al.. “Clinical characteristics and outcomes of acute liver failure in neonates: a retrospective cohort in China.” European journal of pediatrics (2024). PMID: 38689183 ↗
L2OTHERCited in: Decompensation & Transplant Management - [129]
Teschke R. “Hemochromatosis: Ferroptosis, ROS, Gut Microbiome, and Clinical Challenges with Alcohol as Confounding Variable.” International journal of molecular sciences (2024). PMID: 38473913 ↗
L5REVIEW_NARRATIVECited in: Decompensation & Transplant Management - [130]
Almomani A, Kumar P, Onwuzo S et al.. “Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature.” Journal of gastroenterology and hepatology (2022). PMID: 36328950 ↗
L2REVIEW_NARRATIVECited in: Decompensation & Transplant Management - [131]
Ellervik C, Birgens H, Tybjaerg-Hansen A et al.. “Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls.” Hepatology (Baltimore, Md.) (2007). PMID: 17828789 ↗
L1SR_OBSCited in: Complications - [132]
Hamann V, Hook S, Sujariyakul P et al.. “In vivo base editing alleviates hepatic iron accumulation and fibrosis in models of HFE-related hereditary hemochromatosis.” Journal of hepatology (2026). PMID: 42269836 ↗
L2OTHERCited in: Complications - [133]
Dragani TA. “Risk of HCC: genetic heterogeneity and complex genetics.” Journal of hepatology (2009). PMID: 20022654 ↗
L5REVIEW_NARRATIVECited in: Complications - [134]
Allen KJ, Gurrin LC, Constantine CC et al.. “Iron-overload-related disease in HFE hereditary hemochromatosis.” The New England journal of medicine (2008). PMID: 18199861 ↗
L2OTHERCited in: Complications - [135]
Mottelson M, Glenthøj A, Nordestgaard BG et al.. “Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individuals.” Blood (2024). PMID: 38728387 ↗
L2COHORTCited in: Complications - [136]
Livin M, Sebai A, Tzedakis S et al.. “Combination of a Glissonean Approach and Indocyanine Green Fluorescence Imaging to Perform a Laparoscopic Right Anterior Sectionectomy.” Annals of surgical oncology (2024). PMID: 38506935 ↗
L4CASE_REPORTCited in: Complications - [137]
Gurrin LC, Osborne NJ, Constantine CC et al.. “The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis.” Gastroenterology (2008). PMID: 18848943 ↗
L2OTHERCited in: Prognosis & Natural History - [138]
Yu L, Ioannou GN. “Survival of liver transplant recipients with hemochromatosis in the United States.” Gastroenterology (2007). PMID: 17681170 ↗
L2OTHERCited in: Prognosis & Natural History - [139]
Agaisse T, Thomson C, Balmaceno-Criss M et al.. “Acute spinal cord compression in the setting of chronic extramedullary hematopoiesis of the thoracic spine.” North American Spine Society journal (2023). PMID: 37649971 ↗
L4CASE_REPORTCited in: Prognosis & Natural History - [140]
Acton RT, Barton JC, Passmore LV et al.. “Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18585964 ↗
L2OTHERCited in: Special Populations & Prevention - [141]
Zin OA, Neves LM, Cunha DP et al.. “Genotypic-Phenotypic Correlations of Hereditary Hyperferritinemia-Cataract Syndrome: Case Series of Three Brazilian Families.” International journal of molecular sciences (2023). PMID: 37569253 ↗
L4CASE_REPORTCited in: Special Populations & Prevention - [142]
Młodziński K, Świątczak M, Kaufmann D et al.. “From Iron Deficiency to Overload: A Missing Link in the Mechanisms of Cardiac Autonomic Nervous System Dysfunction.” Journal of clinical medicine (2026). PMID: 41827288 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Prevention - [143]
Bakur K, Hamid H, Alhaddad B et al.. “Adult genomic medicine: lessons from a multisite study of 2700 patients.” Genome medicine (2025). PMID: 41024252 ↗
L2OTHERCited in: Special Populations & Prevention